Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | GRM8 | O00222 | 1/20 | 0.48 |
| ▸ | GRM6 | O15303 | 1/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.48 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.48 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2502565 | 0.78 | GRM8 (0.57) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL2502561 | 0.78 | GRM8 (0.57) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL5074626 | 0.77 | CYP1A2 (0.56) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL25384088 | 0.76 | CYP1A2 (0.71) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL4305231 | 0.76 | CYP1A2 (0.71) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL4652465 | 0.73 | CYP1A2 (0.43) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL23897449 | 0.73 | GABRP (0.56) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL2928348 | 0.72 | GRM8 (0.54) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL15124709 | 0.72 | GRM8 (0.54) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| D-Glutamate SCHEMBL518392 | 0.69 | GRM8 (0.95) | CYP1A2GRM8GRM6GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585846-B2 | Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof | UNIVERSITY OF ROCHESTER (US) | 2009-09-08 | — | — | US | claimed |
| US-12011428-B2 | Compositions and methods for stimulating ventilatory and/or respiratory drive | CASE WESTERN RESERVE UNIVERSITY (US) | 2024-06-18 | — | — | US | disclosed |
| US-20230338319-A1 | COMPOSITIONS AND METHODS FOR STIMULATING VENTILATORY AND/OR RESPIRATORY DRIVE | CASE WESTERN RESERVE UNIVERSITY | 2023-10-26 | — | — | US | disclosed |
| US-20210017402-A1 | ANTI-FOULING PAINTS AND COATINGS | REACTIVE SURFACES, LTD., LLP (US) | 2021-01-21 | — | — | US | disclosed |
| US-20200354588-A1 | ANTI-FOULING PAINTS AND COATINGS | REACTIVE SURFACES, LTD., LLP (US) | 2020-11-12 | — | — | US | disclosed |
| US-20140083324-A1 | Anti-fouling Paints and Coatings | REACTIVE SURFACES, LTD (US) | 2014-03-27 | — | — | US | disclosed |
| US-6423744-B2 | ADMINISTERING AN AMOUNT OF A LEUKOTRIENE B4 (LTB4) ANTAGONIST, PREFERABLY A LTB4 RECEPTOR ANTAGONISTIC, TO A PATIENT EXHIBITING ADVERSE DRUG EFFECT DUE TO EXOGENOUS INTERLEUKIN-2, TO DECREASE THE ADVERSE EFFECTS | BIOMEDICINES, INC. | 2002-07-23 | — | — | US | disclosed |
| US-20020016360-A1 | Method of diminishing the adverse effects of interleukin-2 | INTARCIA THERAPEUTICS, INCORPORATED | 2002-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016360-A1 | Method of diminishing the adverse effects of interleukin-2 | LTB4R2, IL2, LTB4R | CYP1A2 397/4885GRM8 2336/4885GRM6 2422/4885 |
| US-12011428-B2 | Compositions and methods for stimulating ventilatory and/or respiratory drive | GSTM1, GSTO1, GSR | CYP1A2 1422/4885GRM8 276/4885GRM6 507/4885 |
| US-20230338319-A1 | COMPOSITIONS AND METHODS FOR STIMULATING VENTILATORY AND/OR RESPIRATORY DRIVE | GSTM1, GSTO1, GSR | CYP1A2 1422/4885GRM8 276/4885GRM6 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.